Travere Therapeutics: Valuation Suggests A Buy (NASDAQ:TVTX)

seekingalpha.com · 2026-08-19

Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. Click here to read more about the TVTX stock.